SGO 2020 Annual Meeting

In an exploratory analysis of a phase 3 study, niraparib improved progression-free survival in patients with advanced ovarian cancer across all important subgroups. Read More ›

Preliminary data on time to first subsequent therapy and second progression-free survival support clinical benefit of niraparib over placebo. Read More ›

New research shows that treatment with niraparib does not negatively impact quality of life in patients with ovarian cancer. Read More ›

Initial findings from a large-scale, patient-reported outcomes program reveal that patients with gynecologic malignancy do not report worse quality of life after surgery. Read More ›

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: